Kevin Z. Chao, MD, Daniel J. Riskin, MD, MBA, and Thomas M. Krummel, MD
Stanford’s Biodesign Program brings together students and postgraduates in medicine, engineering, law, and business to embark on a 1- to 2-year fellowship in medical device innovation.
All of us who are pursuing solutions to the obesity epidemic face clinical, ethical, and regulatory challenges. First among them is the significant role of individual lifestyle and behavior choices in causing obesity.
The guidelines for patients’ eligibility for bariatric surgery have not changed since 1991, although recent data suggest there may be indications for broadening application of the surgery.
Forced migration of Pacific Islanders raises ethical issues of health and health care disparities, which are examined in the case of Tuvaluan immigrants.
AMA J Ethics. 2017;19(12):1211-1221. doi:
10.1001/journalofethics.2017.19.12.imhl1-1712.
“Difficult” patient-physician encounters have roots in uncertainty about individuals’ trustworthiness, clinicians’ skills and training, and medical science.
AMA J Ethics. 2017;19(4):391-398. doi:
10.1001/journalofethics.2017.19.4.mhst1-1704.
The rationale for policy intervention to reduce obesity rates appears compelling. Justification for intervening in the case of children is particularly strong, and precedent suggests that society will more readily accept appropriate restrictions to youth behavior.
A discussion of the ethical issues raised by a patient’s request for off-label, prophylactic bariatric surgery to prevent diabetes mellitus type 2 (DM type 2).
A discussion of the ethical issues raised by a patient’s request for off-label, prophylactic bariatric surgery to prevent diabetes mellitus type 2 (DM type 2).
Does a surgeon’s complication rate in a randomized controlled trial constitute a “significant new finding” that must be reported to patients during the consent process?